TY - JOUR
T1 - Pharmacokinetics of Amikacin after Intravenous Intramuscular and Subcutaneous Administration in German Shepherd Dog
AU - , Yongxue Sun AU - Dai, Zhenqing AU - , Yuanqing Lin AU - , Yanying Yu AU - , Dongping Zeng
JO - Journal of Animal and Veterinary Advances
VL - 11
IS - 8
SP - 1145
EP - 1148
PY - 2012
DA - 2001/08/19
SN - 1680-5593
DO - javaa.2012.1145.1148
UR - https://makhillpublications.co/view-article.php?doi=javaa.2012.1145.1148
KW - Amikacin
KW -German Shepherd dog
KW -pharmacokinetics
KW -LC-MS/MS
KW -plasma injections
KW -China
AB - The purpose of the study was to compare the pharmacokinetics of amikacin in German Shepherd dogs following single intravenous intramuscular and subcutaneous injections. Amikacin was administrated by a randomized three cross-over design after single intravenous (10 mg kg-1) intramuscular (10 mg kg-1) and subcutaneous injections (10 mg kg-1) in 9 healthy German Shepherd dogs. The concentrations of Amikacin in plasma were determined by LC-MS/MS and the concentration-time data were analyzed with 3 p97 program. It’s best to fit the amikacin concentration-time data to two-compartment open model after single i.v. dosing. The main pharmacokinetic parameters were as follows: T1/2β = (1.61±0.07) h, Vc = (0.10±0.01) L kg-1, CL(s) = (0.08±0.01) l kg-1 ·h, AUC = (129.15±6.74) μg mL-1 ·h. A two-compartment model with first order absorption best described the drug concentration-time data after single i.m. and s.c. in healthy dogs. The main pharmacokinetic parameters were as follows: T1/2α = (0.49±0.07) h and (0.64±0.08) h, respectively; T1/2β = (1.40±0.12) h and (1.78±0.15) h, respectively; Tpeak = (0.79±0.09) h and (0.89±0.07) h, respectively; Cmax = (44.59±2.10) μg mL-1 and (31.42±1.39) μg mL-1, respectively; F = (91.3±6.6) and (81.0±5.6)%, respectively.
ER -